#United States #Princeton #CytoSorbents #Ticagrelor #CABG

CytoSorbents Announces Promising New Data on Bleeding Reduction in CABG Surgery

In a significant advance for patients undergoing urgent cardiac surgeries, CytoSorbents Corporation has reported compelling new findings that demonstrate the efficacy of CytoSorb in reducing severe bleeding during Coronary Artery Bypass Grafting (CABG) procedures for patients taking the blood-thinning medication Ticagrelor. The results were unveiled at the recent European Society of Cardiology (ESC) Congress, attracting the attention of healthcare professionals and researchers worldwide, given the potentially life-saving implications of these findings.

The Clinical Dilemma of Bleeding Risks in Cardiac Surgery

Patients who require urgent cardiac interventions while on potent anticoagulants such as Ticagrelor face heightened risks of significant bleeding, which complicates surgical procedures and can result in serious postoperative complications. Historically, surgeries for these patients have had to be postponed for several days to allow the anticoagulant to dissipate, but this delay can exacerbate the patient's condition. The introduction of CytoSorb has provided a crucial alternative, enabling the removal of Ticagrelor and offering a more immediate solution.

Key Findings of the Study

The latest patient-level matched analysis illustrates a substantive 37% relative reduction in severe bleeding events among CABG patients who received CytoSorb during their procedures. Specifically, the analysis compared 198 patients who were treated with CytoSorb to 389 patients who did not receive this intervention. The findings suggest that:

• - Severe Bleeding Reduction: The relative incidence of BARC-4 severe bleeding was significantly lower in the CytoSorb group (21.8%) compared to controls (34.5%), with a p-value of 0.002 indicating strong statistical significance.
• - Reduced Need for Transfusions: There were also notable decreases in 24-hour chest tube drainage and the requirement for red blood cell transfusions.
• - Safety Profile: Importantly, the study reported no serious device-related adverse events, corroborating the safety of using CytoSorb during these high-risk surgeries.

Expert Consensus on Results

Prof. Dr. Uwe Zeymer from the Institute for Heart Attack Research articulated the importance of these findings, asserting that the robust statistical adjustments used in their analysis illustrate a clear advantage in using CytoSorb for patients on Ticagrelor undergoing urgent CABG. Moreover, the number needed to treat to prevent a single severe bleeding event was determined to be just eight, emphasizing the clinical relevance of this data.

Pathways to Regulatory Approval

CytoSorbents is actively working towards enhancing the regulatory landscape for DrugSorb-ATR, which is meant for antithrombotic removal. Their proactive engagement with the FDA during recent pre-submission meetings allowed them to garner constructive feedback on the regulatory pathways available for their devices. These interactions suggest a collaborative approach, aiming to utilize a combination of clinical trial data and new real-world evidence to bolster their submissions.

CEO Dr. Phillip Chan remarked on the promising trajectory these findings present, indicating that they expect these results to substantively strengthen their De Novo submission to the FDA aimed at addressing severe bleeding risks in patients using anticoagulants during urgent surgical procedures.

Conclusion: A Hopeful Future for Cardiac Surgery

As CytoSorbents perseveres in their mission to optimize patient outcomes during cardiac surgeries, the revelations from this independent analysis signal significant progress in this endeavor. The implications of effectively managing bleeding risks can potentially transform urgent cardiac care, where previously, patients faced delays and increased complications. With continued emphasis on research and collaboration with regulatory bodies, CytoSorbents is poised to enhance the standard of care for patients undergoing CABG while on anticoagulant therapies, reflecting a bright future in the realm of cardiac surgery.

For more details on this significant breakthrough and regulatory updates, visit CytoSorbents.